dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ciardiello, Davide |
dc.contributor.author | Martini, Giulia |
dc.contributor.author | Napolitano, Stefania |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Cervantes, Andrés |
dc.contributor.author | Ciardiello, Fortunato |
dc.date.accessioned | 2022-09-12T08:22:48Z |
dc.date.available | 2022-09-12T08:22:48Z |
dc.date.issued | 2022-07 |
dc.identifier.citation | Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022 Jul;72(4):372–401. |
dc.identifier.issn | 1542-4863 |
dc.identifier.uri | https://hdl.handle.net/11351/8137 |
dc.description | Immunoteràpia; Càncer colorectal metastàtic; Medicina de precisió |
dc.description.sponsorship | Fortunato Ciardiello was supported by a grant from Regione Campania (I-Cure Research Project Cup 21C17000030007). Andres Cervantes was supported by grants from the Instituto de Salud Carlos III (PI18/01909 and PI21/00689). Fortunato Ciardiello reports institutional research grants from Amgen, Merck KGaA, Merck Sharp & Dohme, Pfizer, Pierre Fabre, Roche, and Servier; and service on advisory boards for Bayer, Merck KGaA, Merck Sharp & Dohme, Pierre Fabre, Roche, and Servier outside the submitted work. Davide Ciardiello reports a travel grant from Sanofi outside the submitted work. Stefania Napolitano reports honoraria from Bristol Myers Squibb and Novartis outside the submitted work. Josep Tabernero reports advisory board or scientific consultancy fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Roche, Genentech, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck KGaA, Merus, Merck Sharp & Dohme, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, SotioBiotech, Taiho, Tessa Therapeutics, and TheraMyc outside the submitted work. Andres Cervantes reports institutional research grants from Genentech, Merck KGaA, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, and Fibrogen; and honoraria or speaker’s fees from Amgen, Merck KGaA, Roche, Bayer, Servier, and Pierre Fabre outside the submitted work. Giulia Martini reports no conflicts of interest. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | CA: A Cancer Journal for Clinicians;72(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Medicina personalitzada |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Precision Medicine |
dc.title | Clinical management of metastatic colorectal cancer in the era of precision medicine |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3322/caac.21728 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /terapia |
dc.subject.decs | medicina de precisión |
dc.relation.publishversion | https://doi.org/10.3322/caac.21728 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ciardiello F, Martini G, Napolitano S] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Ciardiello D] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Division of Medical Oncology, IRCCS Foundation Home for the Relief of Suffering, San Giovanni Rotondo, Italy. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology, University of Vic/Central University of Catalonia, Barcelona, Spain. Oncology Institute of BarcelonaQuironsalud, Biomedical Research Center in Cancer, Barcelona, Spain. [Cervantes A] Medical Oncology Department, Instituto de Investigación Sanitaria Valencia Biomedical Research Institute, University of Valencia, Valencia Spain. Carlos III Institute of Health, Biomedical Research Center in Cancer, Madrid, Spain |
dc.identifier.pmid | 35472088 |
dc.identifier.wos | 000787357900001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |